IDH野生型组织学2-3级胶质瘤的长期结局
该回顾性队列纳入1996-2019年134例组织学2-3级IDH野生型成人胶质瘤,中位随访29.8个月,中位OS 35个月、中位PFS 20.9个月;2级肿瘤生存优于3级,3级肿瘤生存与分子胶质母细胞瘤相当,同步放化疗较序贯治疗未带来生存优势。
要点
- 组织学2级IDH野生型胶质瘤中位OS达94.5个月,明显优于3级的29.8个月。
- 3级IDH野生型胶质瘤生存与分子胶质母细胞瘤相当,需按高级别对待。
- 3级肿瘤中同步放化疗较序贯治疗未显示生存优势(P=0.17)。
核心结论
- 组织学2-3级IDH野生型胶质瘤结局异质,3级生存与分子胶质母细胞瘤相当,部分2级生存期长。
- 3级肿瘤中同步放化疗较序贯治疗未带来生存优势,支持重新评估部分患者的治疗强度。
研究设计与样本
- 回顾性识别1996-2019年诊断的组织学2-3级IDH野生型胶质瘤成人患者,共134例,中位随访29.8个月。
- 采用Kaplan-Meier法估计OS和PFS,Cox回归评估预后因素。
- 针对年龄>55岁或接受NGS IDH检测者进行亚组分析以排除非经典IDH突变。
主要发现
- 全队列中位OS为35个月(95%CI:28.8-43),中位PFS为20.9个月(95%CI:14.5-27.4)。
- 2级肿瘤中位OS为94.5个月、中位PFS为50.6个月,3级肿瘤中位OS为29.8个月、中位PFS为15.3个月。
- 3级肿瘤中序贯放化疗中位OS为29.8个月,同步放化疗后化疗中位OS亦为29.8个月(P=0.17);中位PFS分别为22.2个月与(原文未给出对照值)。
关键数值与推荐
- 组织学2级IDH野生型胶质瘤中位OS 94.5个月、中位PFS 50.6个月。
- 组织学3级IDH野生型胶质瘤中位OS 29.8个月、中位PFS 15.3个月。
- 3级肿瘤序贯放化疗与同步放化疗后化疗中位OS均为29.8个月(P=0.17)。
临床怎么用
- 组织学3级IDH野生型胶质瘤应按分子胶质母细胞瘤级别评估预后与治疗。
- 对部分3级IDH野生型患者,同步放化疗较序贯治疗未显示生存优势,可个体化评估治疗强度。
- 组织学2级IDH野生型胶质瘤中部分患者生存期长,治疗决策需结合分子特征。
局限性
- 回顾性研究设计,存在选择偏倚可能。
- 样本量134例,中位随访29.8个月,长期结局数据有限。
- IDH野生型判定部分依赖年龄>55岁或NGS检测亚组分析,非全部患者经NGS确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: IDH-wt diffuse gliomas with histologic grade 2-3 features and distinct molecular characteristics are now classified as molecular glioblastoma, yet outcomes and optimal management remain incompletely defined in a contemporary cohort. METHODS: Adults with histologic grade 2-3 IDH-wt gliomas diagnosed from 1996 to 2019 were retrospectively identified. Overall survival (OS) and progression-free survival (PFS) were estimated using Kaplan-Meier methods, with Cox regression used to assess prognostic factors. To account for noncanonical IDH mutations, subgroup analyses were performed in those age > 55 or with next generation sequence (NGS) IDH testing. RESULTS: A total of 134 patients were included, with a median follow-up of 29.8 months. Median OS was 35 months (95% CI: 28.8-43), and median PFS was 20.9 months (95% CI: 14.5-27.4). Grade 2 tumors demonstrated significantly improved outcomes compared to grade 3 tumors (median OS 94.5 vs. 29.8 months; median PFS 50.6 vs. 15.3 months). Among grade 3 tumors, sequential radiation and chemotherapy yielded a median OS of 29.8 months versus 29.8 months with concurrent chemoradiation followed by chemotherapy (p = 0.17); median PFS was 22.2 months versus. CONCLUSION: IDH-wt gliomas with grade 2-3 histology have heterogeneous outcomes. Grade 3 tumors show survival comparable to molecular glioblastoma, while a subset of grade 2 tumors exhibit prolonged survival. Concurrent chemoradiation did not confer a survival advantage over sequential therapy in grade 3 tumors, supporting reevaluation of treatment intensity in selected patients.
引用
- Carriere PP, Haisraely O, Aaroe A, et al. Long-term outcomes in IDH-wildtype (IDH-wt) gliomas with historical WHO grade 2 and 3 histology. J Neurooncol. 2026. PMID: 42489814. doi:10.1007/s11060-026-05712-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。